Jingyao Su1, Danyang Chen1, Ruilin Zheng1, Xia Liu1, Mingqi Zhao1, Bing Zhu2, Yinghua Li3. 1. Center Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510120, China. 2. Center Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510120, China. zhubing@gzhmu.edu.cn. 3. Center Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510120, China. liyinghua@gzhmu.edu.cn.
Abstract
BACKGROUND: The H1N1 influenza virus causes acute respiratory tract infection, and its clinical symptoms are very similar to those of ordinary influenza. The disease develops rapidly. If the flu is not treated, complications such as pneumonia, respiratory failure, and multiple organ damage can occur, resulting in a high fatality rate. Influenza virus mutates rapidly. At present, there is no specific drug for H1N1, so it is an urgent need for clinical care to find new drugs to treat H1N1. MATERIALS AND METHODS: The polysaccharide derived from Durvillaea Antarctica green algae has a certain antiviral effect. In this study, the results of CCK-8, apoptosis cycle detection, JC-1 and Western blotting proved that Duvira Antarctic polysaccharide (DAPP) has the ability to inhibit H1N1 infection. RESULTS: CCK-8 test showed that the DAPP with concentration at 32 μg/mL had no toxicity to MDCK cells. In addition, DAPP reduced cell apoptosis by inhibiting the ERK signaling pathway. Meanwhile, DAPP could increase the expression of STAT3 and significantly inhibited proinflammatory cytokines. CONCLUSIONS: In summary, these results suggested that DAPP may be potential with the ability to resist the H1N1 influenza virus.
BACKGROUND: The H1N1 influenza virus causes acute respiratory tract infection, and its clinical symptoms are very similar to those of ordinary influenza. The disease develops rapidly. If the flu is not treated, complications such as pneumonia, respiratory failure, and multiple organ damage can occur, resulting in a high fatality rate. Influenza virus mutates rapidly. At present, there is no specific drug for H1N1, so it is an urgent need for clinical care to find new drugs to treat H1N1. MATERIALS AND METHODS: The polysaccharide derived from Durvillaea Antarctica green algae has a certain antiviral effect. In this study, the results of CCK-8, apoptosis cycle detection, JC-1 and Western blotting proved that Duvira Antarctic polysaccharide (DAPP) has the ability to inhibit H1N1 infection. RESULTS: CCK-8 test showed that the DAPP with concentration at 32 μg/mL had no toxicity to MDCK cells. In addition, DAPP reduced cell apoptosis by inhibiting the ERK signaling pathway. Meanwhile, DAPP could increase the expression of STAT3 and significantly inhibited proinflammatory cytokines. CONCLUSIONS: In summary, these results suggested that DAPP may be potential with the ability to resist the H1N1 influenza virus.
Authors: Sarah L Londrigan; Kirsty R Short; Joel Ma; Leah Gillespie; Steven P Rockman; Andrew G Brooks; Patrick C Reading Journal: J Virol Date: 2015-09-30 Impact factor: 5.103
Authors: Petr Chlanda; Elena Mekhedov; Hang Waters; Alexander Sodt; Cindi Schwartz; Vinod Nair; Paul S Blank; Joshua Zimmerberg Journal: J Virol Date: 2017-10-13 Impact factor: 5.103